Skip to content
preclinicalSleep & Recovery

Orexin-A

Also known as: Hypocretin-1, HCRT-1, OX-A

Orexin-A is a 33-amino-acid neuropeptide produced exclusively by a small cluster of ~70,000 neurons in the lateral hypothalamus. It is essential for maintaining wakefulness, regulating appetite, and stabilizing sleep-wake transitions. Loss of orexin neurons causes narcolepsy type 1 — the discovery of this connection in 1998 was a breakthrough that launched an entire drug class. Dual orexin receptor antagonists (DORAs) like suvorexant and lemborexant are now FDA-approved sleep aids, while orexin agonists are being developed for narcolepsy.

4 cited references·5 researched benefits

Quick Answer

Orexin-A (Hypocretin-1) is a 33-amino-acid wake-promoting neuropeptide produced by lateral hypothalamic neurons. Its discovery in 1998 revealed that orexin neuron loss causes narcolepsy type 1. This breakthrough spawned two drug classes: dual orexin receptor antagonists (DORAs) like suvorexant for insomnia (blocking wakefulness), and orexin receptor agonists for narcolepsy (restoring wakefulness). Orexin-A also regulates appetite, reward, and autonomic function.

Key Facts

Mechanism
Orexin-A binds two GPCRs: OX1R (Gq-coupled, high affinity) and OX2R (Gq/Gi-coupled, equal affinity with orexin-B). Orexin neurons in the lateral hypothalamus project widely to monoaminergic arousal centers: locus coeruleus (norepinephrine), tuberomammillary nucleus (histamine), dorsal raphe (serotonin), and ventral tegmental area (dopamine). Orexin-A stabilizes the "flip-flop switch" between wakefulness and sleep — without orexin, transitions become unstable, causing the sudden sleep attacks and cataplexy of narcolepsy. Beyond sleep-wake regulation, orexin neurons integrate metabolic signals (glucose, leptin, ghrelin) to coordinate arousal with energy status, ensuring animals stay awake when hungry.
Research Status
preclinical
Half-Life
~30 minutes (CSF)
Molecular Formula
C₁₅₂H₂₄₃N₄₇O₄₄S₂
Primary Use
Sleep & Recovery
Table of Contents

Benefits

  • Wakefulness maintenance — essential for stable arousal and prevention of inappropriate sleep intrusions during wakingstrong
  • Narcolepsy drug target — orexin pathway discovery produced FDA-approved DORAs for insomnia and agonists in development for narcolepsystrong
  • Sleep-wake stabilization — orexin prevents fragmented sleep and inappropriate transitions between wake and REM sleepstrong
  • Appetite-arousal integration — coordinates metabolic status with wakefulness, an elegant evolutionary mechanismmoderate
  • Reward and motivation modulation — orexin neurons project to VTA dopamine neurons, influencing motivation and reward-seekingmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use only (intranasal and intrathecal in clinical trials)VariableN/AOrexin-A is not commercially available as a therapeutic. Orexin receptor agonists (e.g., TAK-994, danavorexton) are in clinical development for narcolepsy. DORAs (suvorexant, lemborexant) block orexin receptors for insomnia treatment. Intranasal orexin-A has been explored in research settings.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Sympathetic activation — orexin-A increases heart rate, blood pressure, and sympathetic tonecommon
  • Appetite stimulation — orexigenic effects may promote food intake and weight gaincommon
  • Sleep disruption — excessive orexin signaling could cause insomnia or prevent appropriate sleep onsetcommon
  • Anxiety — orexin activates stress-related circuits in the amygdala and hypothalamusrare

Frequently Asked Questions

How did the discovery of orexin change sleep medicine?
In 1998, two groups independently discovered the orexin/hypocretin system. Emmanuel Mignot's group at Stanford found that canine narcolepsy was caused by mutations in the OX2R gene, while Masashi Yanagisawa's group found that orexin knockout mice developed narcolepsy-like symptoms. The subsequent finding that human narcolepsy type 1 involves autoimmune destruction of orexin neurons transformed sleep medicine — enabling diagnostic CSF orexin testing and spawning the DORA drug class (suvorexant, lemborexant, daridorexant) for insomnia.
What are DORAs and how do they work?
Dual Orexin Receptor Antagonists (DORAs) block both OX1R and OX2R, counteracting orexin's wake-promoting effects to facilitate sleep. FDA-approved DORAs include suvorexant (Belsomra, 2014), lemborexant (Dayvigo, 2019), and daridorexant (Quviviq, 2022). Unlike benzodiazepines and Z-drugs that broadly suppress brain activity via GABA enhancement, DORAs specifically target the wake-promoting system, potentially producing more natural sleep architecture with less next-day impairment.
Can orexin replacement treat narcolepsy?
Yes, this is an active area of development. Since narcolepsy type 1 is caused by orexin neuron destruction, directly replacing orexin or activating its receptors is the most logical therapy. The oral OX2R agonist TAK-994 showed dramatic efficacy in a phase 2 trial (reducing excessive daytime sleepiness and cataplexy) but was suspended due to liver safety signals. Other orexin agonists (danavorexton) are in development. If successful, orexin replacement would be the first disease-modifying treatment for narcolepsy.
Why does loss of orexin neurons cause narcolepsy but not starvation?
While orexin promotes both wakefulness and feeding, redundant appetite systems (NPY, AgRP, ghrelin, leptin) compensate for orexin loss to maintain adequate food intake. However, no system adequately compensates for orexin's unique role in stabilizing the sleep-wake "flip-flop switch." Without orexin, the boundary between wakefulness and REM sleep becomes unstable, leading to narcolepsy's hallmark symptoms: excessive daytime sleepiness, cataplexy (intrusion of REM atonia into wakefulness), and sleep paralysis.
Does orexin-A affect exercise performance?
Orexin neurons are activated by physical activity and contribute to exercise-induced wakefulness and sympathetic arousal. Animal studies show that orexin enhances physical activity levels and energy expenditure. Some researchers hypothesize that the orexin system links physical fitness to better sleep quality — exercise increases orexin neuron activity during the day, which may strengthen the sleep-wake contrast. However, direct evidence for orexin-A as a performance-enhancing agent in humans is lacking.

References

  1. 1
    Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation(1999)PubMed ↗
  2. 2
    The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity(1998)PubMed ↗
  3. 3
    Orexin receptor antagonists for insomnia: from neuroscience to clinical practice(2019)PubMed ↗
  4. 4
    Orexin/hypocretin system: role in sleep, energy homeostasis, and reward(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19